Longeveron INC 8-K filings

Longeveron's third quarter 2024 results show significant revenue growth and advancements in clinical trials for Lomecel-BTM.

Longeveron announced positive Phase 2a clinical trial results for Lomecel-B in Alzheimer's disease, secured key FDA designations, and raised sufficient capital to fund operations through the fourth quarter of 2025.

Longeveron Inc. has announced a $9 million registered direct offering, alongside a private placement of warrants, to fund its ongoing clinical and regulatory development.

Longeveron Inc. has been granted Fast Track designation by the FDA for its Lomecel-BTM therapy in the treatment of mild Alzheimer's disease, aiming to expedite its development and review.

Longeveron's Lomecel-BTM has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for the treatment of mild Alzheimer's disease, marking a significant milestone for the company.

Longeveron Inc. held its annual meeting on July 2, 2024, where stockholders elected four directors, approved an amendment to the incentive award plan, and ratified the appointment of Marcum LLP as the company's independent auditor.

Longeveron Inc. has successfully raised $4.4 million by inducing the exercise of existing warrants and issuing new warrants, with the funds earmarked for clinical development and general corporate purposes.

Longeveron has announced planned changes to its Board of Directors, including the appointment of Richard Kender and the nomination of Roger Hajjar and Neha Motwani, alongside the resignations of Jeffrey Pfeffer and Cathy Ross.

Longeveron Inc. has successfully closed a warrant exercise, raising $6.2 million, and combined with a previous public offering, has secured a total of $11.4 million to advance its clinical programs.

Longeveron Inc. has successfully closed a public offering, raising approximately $5.2 million to support its ongoing clinical and regulatory development efforts.

Longeveron Inc. has approved a 1-for-10 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

Longeveron Inc. received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share, placing the company at risk of delisting.

Longeveron Inc. stockholders have approved a reverse stock split and the potential adjournment of a special meeting to solicit additional proxies.